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Small-molecule control of insulin and PDGF receptor signaling
and the role of membrane attachment
Jian-xin Yang*, Karen Symes†‡, Mark Mercola† and Stuart L. Schreiber*
Background: Receptor tyrosine kinases (RTKs) regulate the proliferation,
differentiation and metabolism of cells, and play key roles in tissue repair,
tumorigenesis and development. To facilitate the study of RTKs, we have made
conditional alleles that encode monomeric forms of the normally
heterotetrameric insulin receptor and monomeric platelet-derived growth factor
(PDGF) β receptors fused to the FK506-binding protein 12 (FKBP12). The
chimeric receptors can be induced to undergo dimerization or oligomerization
by a small synthetic molecule called FK1012, and the consequences were
studied in cells and embryonic tissues. 
Results: When equipped with an amino-terminal plasma membrane localization
sequence and expressed in HEK293 cells, these chimeric receptors could
signal to downstream targets as indicated by the FK1012-dependent activation
of p70 S6 kinase (p70S6k) and mitogen-activated protein (MAP) kinase. In
Xenopus embryos, the engineered PDGF receptor protein induced the
formation of mesoderm from animal-pole explants in an FK1012-dependent
manner. A cytosolic variant of the protein underwent efficient
transphosphorylation, yet failed to activate appreciably either p70S6k or MAP
kinase following treatment with FK1012. These results provide evidence of a
requirement for membrane localization of RTKs, consistent with current models
of RTK signaling.
Conclusion:  We have developed an approach using the small molecule
FK1012 to conditionally activate chimeric proteins containing FKBP fused to
the insulin receptor or to the PDGF β receptor. Using this system, we were able
to induce mesoderm formation in Xenopus animal-cap tissue and to
demonstrate that membrane localization is required for RTK signaling in
transfected cells. This system should allow the further dissection of RTK-
mediated pathways.
Background
A generally applicable method for the activation of cellular
proteins using small organic molecules called chemical
inducers of dimerization (CIDs) has been developed.
CIDs have thus far been derived primarily from FK506,
cyclosporin, and rapamycin. These natural products and
their synthetic derivatives bind to the natural and mutant
immunophilin domains FK506-binding protein 12
(FKBP12), cyclophilin, and the FKBP12–rapamycin-
binding (FRB) domain of FKBP–rapamycin associated
protein (FRAP) [1]. By using the appropriate CIDs to
trigger the dimerization or oligomerization of functional
domains of various proteins that are fused to
immunophilin dimerization domains, it has been possible
to achieve small-molecule control of signaling mediated
by the T-cell receptor [2,3], Fas [4,5], cadherin [6] and
erythropoietin receptor [7], and by the intracellular pro-
teins Src [8], Sos [9], Raf [10], and ZAP70 [11]. In addi-
tion, CIDs have been used to inducibly translocate
proteins to the plasma membrane [8,9,12] and into [12]
and out of [13] the nucleus, and to regulate gene transcrip-
tion [12,14]. The system has also been used successfully
to induce cell-specific apoptosis and to achieve regulated
synthesis of human growth hormone in mice [5,15].
We have extended this approach to the study of two
members of the receptor tyrosine kinase (RTK) family.
These kinases control cellular proliferation, differentia-
tion and metabolism and have pleiotropic roles in various
physiological and pathological processes [16]. Extensive
studies in recent years have illustrated the principles of
RTK activation and signal transduction, yet questions
regarding the roles of RTKs in normal and disease
processes, and the roles and interactions of individual sig-
naling pathways emanating from specific RTKs remain
unanswered. Conditional alleles of RTKs controlled by
cell-permeable CIDs should facilitate a greater under-
standing of the functions of RTKs. 
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Results and discussion
Conditional forms of the PDGF β and insulin receptors
(designated MFpk3PE and MFpk3IRE, respectively) were
generated by constructing plasmids that encoded chimeric
proteins containing the myristoylation sequence from v-Src
fused to three tandem copies of Fpk, a mutant version of
FKBP12 that fails to interact with calcineurin [12,17], fol-
lowed by the full cytoplasmic tails of the PDGF β receptor
(residues 558–1106) or insulin receptor (residues
942–1343), and by the glu–glu (EE) epitope tag (Figure 1a)
[18]. ∆MFpk3PE is a cytosolic form of MFpk3PE with an
amino-terminal Gly→Ala mutation in the v-Src myristoyla-
tion sequence that prevents myristoylation of the protein.
MFpk3PKRE is a kinase-deficient variant of MFpk3PE with
a Lys643→Arg mutation in the ATP-binding domain of
the PDGF β receptor segment. Figure 1b illustrates
schematically the activation mechanism of the wild-type
PDGF β and insulin receptors by their respective protein
ligands, compared with that of the engineered receptors by
the cell-permeable CID. The wild-type PDGF β receptor
is a monomeric transmembrane protein activated by
ligand-induced dimerization and transphosphorylation
after binding to a bivalent PDGF BB molecule [16,19].
The insulin receptor is a disulfide-bonded hetero-
tetrameric transmembrane protein believed to be activated
by an insulin-induced change in the orientation of the
active sites of the kinase domains, although the exact
mechanism remains unclear [20]. In contrast, our engi-
neered chimeric RTKs, which lack the extracellular ligand-
binding and transmembrane domains, attach to the plasma
membrane intracellularly via an amino-terminal myristoic-
amide moiety and are activated by CIDs such as FK1012
that trigger the dimerization or oligomerization of the
chimeric receptors by binding to two FKBP12 domains
simultaneously [1,2,4–10,12,14,21,22].
To test whether the chimeric PDGF β receptor is acti-
vated by FK1012, we assayed for autophosphorylation of
MFpk3PE in the presence of FK1012. Human embryonic
kidney (HEK) 293 cells were transfected with MFpk3PE,
treated with various doses of FK1012 for 25minutes, and
harvested for immunoblot analysis. As shown in Figure 2a,
FK1012 induced the autophosphorylation of MFpk3PE in
a dose-dependent manner, which was detected in whole-
cell lysates by an anti-phosphotyrosine antibody, 4G10
(Anti-PY). Analysis with an anti-EE-tag antibody (Anti-
EE) [18] revealed equivalent levels of expression of the
chimeric receptor among all samples. Next, we compared
the kinetics of FK1012-induced autophosphorylation of
MFpk3PE to those of PDGF BB-mediated autophospho-
rylation of an EE-tagged wild-type PDGF β receptor
(PDGFRβE) (Figure 2b). PDGF BB induced the rapid
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Figure 1
(a) PDGF β and insulin receptor constructs. M, myristoylation
sequence from v-Src (residues 1–14); ∆M, a mutant form of the
myristoylation sequence with a substitution Gly2→Ala that abolishes
the myristoylation site; Fpk, human FKBP12 with mutations Gly89→Pro
and Ile90→Lys [12,17] (the copy number of Fpk is indicated by the
number following the fragment designation); P and IR, the complete
cytoplasmic domains of the human PDGF β receptor (residues
558–1106) and of the β chain of the insulin receptor (residues
942–1343), respectively; E, Glu-Glu (EE) epitope tag; EC and TM, the
extracellular and transmembrane domains, respectively, of the wild-type
PDGF β receptor; PKR, a kinase-deficient mutant (Lys643→Arg) of the
PDGF β receptor. (b) Schematic representation of the activation of the
insulin and PDGF β receptors by their respective protein ligands or by
a cell-permeable CID. 
autophosphorylation of PDGFRβE followed by the rapid
down-regulation of the activated receptor; FK1012
brought about a similar, albeit slightly slower, response
from MFpk3PE. Such a delay has been observed previ-
ously in other FK1012-dependent processes [3]. The data
in Figure 2c illustrate further the down-regulation of the
chimeric receptor. HEK293 transfectants were treated
with (lanes 2–4) or without (lane 1) 1µM FK1012 for
30 min, then washed and chased in fresh medium for the
indicated times. The signal decreased significantly after
1 hour (lane 3) and reduced to the basal level (lane 1) after
4 hours (lane 4). Similar down-regulation of receptor phos-
phorylation was observed in cells that had been treated
with FK1012 for 4hours (lane 5). Thus, the chimeric
PDGF β receptor retains the ability to be down-regulated,
indicating that the extracellular and transmembrane
domains of the PDGF β receptor are not essential for this
process. This result is consistent with previous findings
showing that the kinase domains and the carboxy-terminal
sequences of RTKs are involved in mediating receptor
down-regulation via endocytosis [23]. 
To check whether the chimeric PDGF β receptor was
able to signal to downstream targets, we examined the
activation of p70S6k by MFpk3PE; the pathway leading to
the activation of this kinase emanates from the PDGF β
receptor and other RTKs [24,25]. We co-transfected
MFpk3PE (or control chimeras) and a plasmid encoding a
hemagglutinin (HA)-tagged rat p70 S6 kinase (HA–p70S6k)
into HEK293 cells. The cells were treated with or without
1µM FK1012 for 25minutes as indicated in Figure 3
before being harvested for an in vitro kinase assay (as
described in Materials and methods). In cells transfected
with MFpk3PE, FK1012 stimulated p70S6k activity,
whereas it had no effect on cells transfected with MFpk3E,
a control construct lacking the cytoplasmic tail of the
PDGF β receptor, nor on cells transfected with
MFpk3PKRE, a control construct lacking kinase activity.
FK1012 alone had no effect on p70S6k activity (Figure 3a).
Figure 3b shows that MFpk3PE and the wild-type PDGFβ receptor are similarly effective in activating p70S6k and
that rapamycin completely inhibits their activity, suggest-
ing that the chimeric and wild-type PDGF receptors share
the same FRAP-mediated pathway that leads to the acti-
vation of p70S6k [24,25]. As described later (see below),
MFpk3PE was also found to activate MAP kinase in the
presence of FK1012. These results suggest that the
chimeric PDGF β receptor is able to signal normally
through its downstream signal transduction pathways.
PDGF receptor signaling is involved in a variety of physi-
ological and pathological processes, including neoplastic
transformation and embryogenesis [16,19]. During verte-
brate development, PDGF α receptor signaling is
required for gastrulation of Xenopus laevis and mice, and
for the development of mesenchyme-derived tissues such
as the craniofacial structure, and of septal structures of the
heart in mice [26–28]; however, PDGF β receptor signal-
ing is essential for development of the cardiovascular,
hematopoietic and renal systems in mice [29]. Conditional
forms of RTKs such as MFpk3PE should allow temporal
and spatial issues concerning the requirement for RTK
signaling during embryonic development to be explored.
We therefore tested whether MFpk3PE could be activated
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FK1012-dependent activation of MFpk3PE. (a) FK1012-triggered
dose-dependent autophosphorylation of MFpk3PE. HEK293 cells were
transfected with vector alone (V) or with MFpk3PE. After starvation in
serum-deficient medium for 24 h, cells were treated with the indicated
amount of FK1012 for 25 min and harvested for immunoblot analysis.
Anti-PY represents immunoblot analysis with an anti-phosphotyrosine
monoclonal antibody 4G10 (1 µg/ml). The band corresponding to the
phosphorylated receptor is indicated by the arrowhead. Anti-EE,
represents immunoblot with a monoclonal antibody against the EE
epitope tag (1 µg/ml). (b) Kinetics of receptor autophosphorylation
induced by FK1012 or by PDGF BB. HEK293 cells were transfected
with PDGFRβE, MFpk3PE or vector alone, and starved of serum as
described above. The cells were treated with 50 ng/ml PDGF BB or
with 1 µM FK1012 for the indicated time, and harvested for
immunoblot analysis as described in (a). (c) Down-regulation of
activated MFpk3PE. HEK293 cells were transfected with MFpk3PE,
starved of serum for 24 h, and treated with 1 µM FK1012 for 30 min
(lanes 2–4) or 4 h (lane 5). The cells were washed three times with
DMEM and chased in medium without FK1012 for 1 h (lane 3) or 4 h
(lane 4) before they were harvested for immunoblot analysis.
by FK1012 in embryonic tissue using Xenopus animal caps
in mesoderm induction assays. Activated growth-factor
receptors have been shown to induce Xenopus presump-
tive ectoderm to form mesoderm [30]. We first introduced
the mRNAs encoding MFpk3PE or control chimeric recep-
tors into two-cell stage Xenopus embryos [31] and then
explanted animal caps at stage 8. The caps were cultured
in the presence or absence of the appropriate ligands until
stage 35 when they were fixed and processed for staining
with hematoxylin–eosin. FK1012 (1µM) induced the for-
mation of loose mesenchymal tissue typical of ventral
mesoderm [32] in animal caps injected with MFpk3PE
(Figure 4a,b), whereas it had no effect on uninjected cap
tissues (Figure 4g,h), caps injected with the control con-
struct MFpk3E (Figure 4c,d), or whole embryos (data not
shown). MFpk3PE showed no background activity in the
absence of FK1012 (compare Figure 4b,h). As a positive
control, we confirmed that PDGF BB could induce the
formation of mesoderm in animal caps injected with the
wild-type PDGF β receptor (Figure 4e,f). 
The insulin receptor may be a special case of an RTK that
could pose a challenge to the proximity-inducing effects
of CIDs such as FK1012. The mature insulin receptor is a
disulfide-bonded heterotetramer comprising two copies
each of the α and β subunits. Insulin binding has been
suggested to induce a conformational change that leads to
receptor activation [20]. The mechanism by which this
conformational change activates the receptor kinase is
unclear, although it may function by juxtaposing the
kinase subunits in much the same way that receptor
dimerization leads to activation of the PDGF β receptor.
Thus, we tested whether direct dimerization of the β sub-
units of the insulin receptor by FK1012 could activate
insulin-receptor signaling. 
We first determined whether the chimeric insulin receptor
MFpk3IRE could be activated by FK1012 at the receptor
level by assaying for its autophosphorylation in HEK293
cells. As shown in Figure 5a, FK1012 (1µM) induced dra-
matic tyrosine phosphorylation of MFpk3IRE followed by
rapid down-regulation of the activated receptor. We then
investigated the phosphorylation of insulin receptor sub-
strate-1 (IRS-1) by FK1012-dependent activation of
MFpk3IRE in HEK293 transfectants. FK1012 stimulated
the phosphorylation of IRS-1 by MFpk3IRE (Figure 5b,
lanes 3,4) to levels comparable to those induced by the
endogenous wild-type insulin receptor (Figure 5b, lanes
1,2). The control construct MFpk3E showed no activity
(Figure 5b, lanes 5,6). When MFpk3IRE was co-trans-
fected with HA–p70S6k into HEK293 cells and the cells
were treated with varying doses of FK1012 for 20minutes,
MFpk3IRE activated p70S6k in an FK1012 dose-dependent
fashion (Figure 6a). A high dose of FK1012 (3µM)
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Figure 3
FK1012-dependent signaling by MFpk3PE. (a)
FK1012-dependent activation of p70S6k by
MFpk3PE. (b) Comparison of the activities of
the chimeric and wild-type PDGF β receptors.
HEK293 cells were co-transfected with
various receptor constructs and HA–p70S6k
as described. After serum starvation for 24 h,
the cells were treated with the indicated
reagents for the following times: 1 µM
FK1012 for 25 min, 50 ng/ml of PDGF BB for
10 min, and 20 nM rapamycin (Rap) for 30
min. The cells were then harvested for
immunoblot analysis and for an in vitro p70S6k
assay. Activity of p70S6k is presented as fold
activation over that detected in
immunoprecipitates from cells transfected
with p70S6k alone. In immunoblot analysis,
HA–p70S6k (HA–p70) was detected with an
HA-specific monoclonal antibody 12CA5
(1 µg/ml), and the receptor proteins were
detected with an anti-EE-epitope-tag
monoclonal antbody (Anti-EE, 1 µg/ml). Data
are representative of three independent
experiments.
appeared to reduce p70S6k activity, possibly because of the
disruption of the dimeric receptor complex (‘dedimeriza-
tion’) by excessive amounts of FK1012 (Figure 6a). We
also examined the activation of MAP kinase by
MFpk3IRE in HEK293 cells that had been co-transfected
with MFpk3IRE and HA-tagged human extracellular-
signal-regulated kinase 1, ERK1 (HA–ERK1). As was
observed for p70S6k, MAP kinase could be activated by the
chimeric insulin receptor in the presence of FK1012
(Figure 6b). The control construct MFpk3E had no effect
on MAP kinase activity either in the presence or in the
absence of FK1012. These results demonstrate that
dimerization or oligomerization of the β subunits of the
insulin receptor is sufficient to activate insulin receptor
signaling, consistent with previous studies on other
chimeric insulin receptors [33,34].
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FK1012 induces mesoderm formation in Xenopus embryos expressing
MFpk3PE. Xenopus embryos at the two-cell stage [31] were
microinjected with synthetic mRNA encoding various receptor
constructs. Animal-pole explants were taken at stage 8 and incubated
with the indicated ligands. The explants were fixed, sectioned and
stained at stage 35. Explants of animal cap tissues from embryos
injected with synthetic mRNA encoding MFpk3PE and treated with (a)
or without (b) 1 µM of FK1012. Explant tissues from embryos injected
with synthetic mRNA encoding MFpk3E (control) and treated with (c)
or without (d) 1 µM FK1012 . Explant tissues from embryos injected
with synthetic mRNA encoding the wild-type PDGF β receptor
(PDGFRβE) treated with 50 ng/ml PDGF BB (e) or left untreated (f).
Animal caps from uninjected embryos treated with (g) or without (h)
1 µM FK1012. Addition of FK1012 to naive tissues or to whole
embryos does not affect development (data not shown). Bar = 100 µm.
Figure 5
FK1012-dependent activation of MFpk3IRE.
(a) FK1012-dependent activation and down-
regulation of MFpk3IRE. HEK293 cells were
transfected with MFpk3IRE, starved of serum
for 24 h, and treated with 1 µM FK1012 for
the indicated times before they were
harvested in 1% NP-40 lysis buffer for
immunoblot analysis with 4G10 antibody. (b)
FK1012-dependent phosphorylation of IRS-1
by MFpk3IRE. HEK293 cells were transfected
with the indicated constructs and cultured in
serum-deficient medium for 24 h before
treatment with 250 ng/ml insulin for 10 min
(lane 2) or 1 µM FK1012 for 25 min (lanes
4,6). The cells were harvested with 1% NP-40
lysis buffer. IRS-1 was precipitated by
incubating the cell lysate with an anti-IRS-1
polyclonal antibody at 4°C for 12 h and
subsequently with protein A–agarose for 2 h.
After extensive washing in lysis buffer, the
immunoprecipitate was separated by
SDS–PAGE and immunoblotted with 4G10
antibody to detect phosphorylated IRS-1. 
The recruitment of Src homology 2 (SH2) domain-con-
taining cytoplasmic proteins such as the p85 subunit of
phosphoinositide 3′ kinase, Shc, Grb2, and phospholi-
pase Cγ [35] to the membrane-inserted, phosphorylated
— activated — receptor is believed to be a critical step in
RTK signal transduction. This process results in a high
effective molarity of the recruited proteins in the vicinity
of their membrane-localized substrates, and thereby
facilitates the ligand-dependent chemistry that takes
place between them. To test this model by determining
whether membrane attachment of an RTK is essential
for downstream signal transduction, we prepared a
cytosolic version of the chimeric PDGF β receptor
∆MFpk3PE that lacks a myristoylation site (Figure 1a). In
HEK293 cells, FK1012 was able to induce the transphos-
phorylation of ∆MFpk3PE receptor to a level similar to
that seen with MFpk3PE (Figure 7a). ∆MFpk3PE,
however, failed to activate p70 S6 kinase appreciably in
the presence of varying doses of FK1012, whereas
MFpk3PE elicited a near 10-fold stimulation (Figure 7b).
Likewise, FK1012-activated ∆MFpk3PE had only mar-
ginal effects on MAP kinase activation, in contrast to the
strong stimulation seen with FK1012-activated MFpk3PE
(Figure 7c). Thus, membrane attachment appears to be
essential for activated RTKs to link to downstream signal
transduction pathways.
Conclusions
We have developed a small-molecule-based approach to
activate insulin and PDGF β receptor chimeras condition-
ally using the FKBP12–FK1012 dimerization system
[1,2,4–10,12,14,21,22]. In this study, we were able to use
this system to induce mesoderm formation in Xenopus
animal cap tissue and to demonstrate that membrane
localization is required for RTK signaling in transfected
cells. This strategy should allow the further dissection of
RTK-mediated pathways in embryonic development and
pathological processes, including oncogenesis and dia-
betes. Our data also suggest that dumbbell-shaped vari-
ants of small molecules comprising two receptor-binding
elements connected by a covalent linkage and that bind
directly to wild-type RTKs should be effective activators
of these receptors. 
Materials and methods
PCR conditions and primers
PCRs were carried out with native Pfu DNA polymerase (Stratagene) in
the manufacturer’s buffer for 25 cycles of 1 min at 94°C, 2 min at 55°C,
and 3 min at 72°C. A cDNA fragment encoding the cytoplasmic domain
of the PDGF β receptor was amplified with primers 5′-ACGCGTCGA-
CAAGAAGCCACGTTACGAGATC-3′ and 5′-AATTTCTAGACTATTC-
CATTGGCATGTATTCCAGGAAGCTATCCTCTGCTTC-3′. The latter
primer also encodes the Glu–Glu epitope tag (EYMPME, single-letter
amino-acid code) [18]. The cytoplasmic domain of the insulin receptor
β chain was amplified with primers 5′-ATATACGCGTCGACAAGAG-
GCAGCCAGATGGGCC-3′ and 5′-AAATCATAGTCGACGGAAG-
GATTGGACCGAGGC-3′. The sequence of the PCR-generated
products was verified by DNA sequencing.
Cell culture and transfection
HEK293 cells were seeded at a density of 3 × 105 cells per 60 mm
dish in medium A (Dulbecco’s modified Eagle’s medium, 100 units/ml
penicillin and 100 µg/ml streptomycin) supplemented with 10%
(vol/vol) fetal calf serum (FCS). The following day (designated day 1),
the cells were transfected by the calcium-phosphate method [36]. The
total amount of DNA was adjusted to 5 µg per dish with the pJY2
vector, a derivative of pcDNA3 in which the three SalI sites were
removed (provided by Brent Stockwell) and the multiple cloning
16 Current Biology, Vol 8 No 1
Figure 6
FK1012-dependent signaling by MFpk3IRE.
(a) FK1012-dose-dependent activation of
p70S6k by MFpk3IRE. HEK293 cells were co-
transfected with MFpk3IRE and HA–p70S6k.
After starvation for 24h in serum-deficient
medium, the cells were treated with the
indicated amounts of FK1012 for 20min, and
harvested for immunoblot analysis (data not
shown) and for an in vitro p70S6k assay.
Activity of p70 S6 kinase is presented as fold
activation over that detected in
immunoprecipitates from cells transfected with
p70S6k alone. (b) FK1012-dependent
activation of MAP kinase by MFpk3IRE.
HEK293 cells were transfected with the
indicated constructs, treated with or without
1 µM FK1012 for 20min as shown, and
harvested for a MAP kinase assay and
immunoblot analysis (data not shown). MAP
kinase activity is presented as fold activation
over the activity detected in
immunoprecipitates from cells transfected with
HA-ERK1 alone. Data presented are
representative of two independent experiments.
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sequence was replaced. On day 2 (24 h after transfection), the
medium was replaced with fresh medium A supplemented with 10%
(vol/vol) FCS. On day 3, the cells were washed with Hank’s buffer and
incubated in fresh medium A supplemented with 0.5% (vol/vol) FCS.
On day 4 (after 24 h serum starvation), the cells were treated with
various reagents and harvested for further analysis.
Immunoblot and kinase assays
For immunoblot analysis, aliquots (30 µg protein/lane) of cell lysate
were separated by SDS—PAGE, transferred to Immobilon polyvinyli-
dene difluoride membrane (Millipore), and blotted with appropriate
antibodies. The immunocomplex was visualized by enhanced chemilu-
minescence (ECL) using an ECL detection system (Amersham). For
the in vitro p70S6k assay, cells were harvested in ice-cold MIPP buffer
(20 mM NaH2PO4, pH 7.4, 1% Triton X-100, 25 µM β-glycerophos-
phate, 0.1 mM Na3VO4, 5 mM NaF, 2 mM EDTA, 2 mM EGTA,
10 µg/ml leupeptin, 10 µg/ml pepstatin, 0.2 mM PMSF and 2 mM
DTT). Half of the total-cell lysate from a 60 mm dish was incubated
with 10 µg of 12CA5 anti-hemagglutinin monoclonal antibody at 4°C
for 2 h and complexed to protein A–agarose beads at 4°C for 1 h. The
precipitate was washed three times with MIPP buffer and once with
kinase reaction buffer (50 mM MOPS, pH 7.2, 10 mM MgCl2, 10 mM
para-nitrophenyl phosphate, 0.1% Triton X-100, 1 mM DTT) at 4°C.
Immunoprecipitates were then incubated at 37°C for 20 min in 25 µl
kinase reaction buffer containing 100 µM ATP, 10 µM [γ-32P]ATP,
1 U/ml protein kinase inhibitor (Sigma), and 50 µM KRRRLASLAA
peptide (single-letter amino-acid code) as substrate. The reaction was
stopped by addition of 100 µM EDTA and incubation at 80°C for
2 min. The reaction mixtures were spotted onto P81 paper, subjected
to four 5 min washes with 500 ml 0.85% H3PO4. The incorporated
radioactivities were measured in a liquid scintillation counter. HA—
p70S6k is a fusion of the HA epitope with the amino-terminus of rat
p70S6k [25] and its expression is driven by the cytomegalovirus (CMV)
promoter. For the in vitro MAP kinase assay, cells were harvested in
lysis buffer (20 mM Tris, pH 7.4, 25 mM β-glycerophosphate, 1 mM
Na3VO4, 5 mM NaF, 2 mM EDTA, 1% NP-40, 10 µg/ml leupeptin,
10 µg/ml pepstatin, 0.2 mM PMSF and 2 mM DTT). HA–ERK1 was
precipitated with 12CA5 monoclonal antibody as described for the
p70S6k assay. The precipitate was washed three times with the lysis
buffer and once with kinase reaction buffer (20 mM Tris, pH 7.4,
10 mM MgCl2, 2 mM MnCl2). Immunoprecipitates were incubated at
30°C for 30 min in 25 µl kinase reaction buffer containing 100 µM ATP,
50 µM [γ-32P]ATP, 1 U/ml protein kinase inhibitor (Sigma), and
50 µg/ml APRTPGGRR peptide (single-letter amino-acid code) as
substrate. The reaction mixtures were spotted onto P81 paper,
washed and counted as described for p70S6k. HA–ERK1 is a fusion of
the HA epitope with the amino-terminus of human ERK1 and its
expression is driven by the CMV promoter.
Xenopus mesoderm induction
The mRNA was synthesized with an SP6 mMESSAGE mMACHINE
kit (Ambion). Xenopus embryos were microinjected at the two-cell
stage with approximately 100 pg of synthetic mRNA. In the mesoderm
induction assay, animal pole explants (caps) were prepared at stage 8.
Explants were cultured in 0.75× MMR [37] with or without the various
ligands until stage 35, then fixed in 4% paraformaldehyde, embedded
in paraffin and sectioned. Histological sections were stained with
hematoxylin–eosin.
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Figure 7
Membrane localization is essential for signal transduction from the
PDGF β receptor. (a) FK1012 activates engineered PDGF β receptors
independent of membrane association. HEK293 cells were transfected
with vector alone (V), MFpk3PE or ∆MFpk3PE. After starvation for 24 h,
the cells were treated with the indicated amount of FK1012 for 25 min
and harvested for immunoblot analysis with 4G10 antibody (Anti-PY)
or with an anti-EE-tag antibody (Anti-EE). PDGF β receptor signaling to
p70S6k (b) and to MAP kinase (c) requires membrane localization of
the receptor. HEK293 cells were transfected with the indicated
plasmids, treated with or without FK1012 as shown, and subjected to
in vitro kinase assays. Activities of p70S6k and MAP kinase are
expressed as fold activation over the respective activities detected in
immunoprecipitates from cells transfected with HA–p70S6k or with
HA–ERK1 alone. Data represent three independent experiments.
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